Tags

Type your tag names separated by a space and hit enter

Recent developments in bisphosphonate therapy.
Semin Arthritis Rheum. 2007 Aug; 37(1):1-12.SA

Abstract

OBJECTIVE

To provide a review of current developments in bisphosphonates indicated for the treatment of several rheumatologic conditions, including postmenopausal and glucocorticoid-induced osteoporosis.

METHODS

This review summarizes the pathology, diagnosis, and treatment of both postmenopausal and glucocorticoid-induced osteoporosis and examines the results of current clinical trials of the newest oral and intravenous formulations of nitrogen-containing bisphosphonates. We discuss important adverse events, including upper gastrointestinal symptoms and osteonecrosis of the jaw. Additionally, we explore methods that may improve patient adherence to bisphosphonate therapy, which is currently suboptimal.

RESULTS

Clinical studies have shown that oral bisphosphonates are efficacious in increasing bone mineral density and reducing risk of fracture. Despite concerns of upper gastrointestinal irritation, most of the newer oral bisphosphonates display a safety profile similar to placebo. Many of the newest formulations offer patients a choice in both dosing frequency and method of administration (either oral or intravenous).

CONCLUSIONS

Nitrogen-containing bisphosphonates are important therapeutic options for the prevention and treatment of osteoporosis.

Authors+Show Affiliations

UCLA/Cedars-Sinai, Osteoporosis Medical Center, Beverly Hills, California 90211, USA. stuarts@omcresearch.orgNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

17303219

Citation

Silverman, Stuart L., and Michael Maricic. "Recent Developments in Bisphosphonate Therapy." Seminars in Arthritis and Rheumatism, vol. 37, no. 1, 2007, pp. 1-12.
Silverman SL, Maricic M. Recent developments in bisphosphonate therapy. Semin Arthritis Rheum. 2007;37(1):1-12.
Silverman, S. L., & Maricic, M. (2007). Recent developments in bisphosphonate therapy. Seminars in Arthritis and Rheumatism, 37(1), 1-12.
Silverman SL, Maricic M. Recent Developments in Bisphosphonate Therapy. Semin Arthritis Rheum. 2007;37(1):1-12. PubMed PMID: 17303219.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Recent developments in bisphosphonate therapy. AU - Silverman,Stuart L, AU - Maricic,Michael, Y1 - 2007/02/14/ PY - 2006/08/11/received PY - 2006/11/21/revised PY - 2006/12/17/accepted PY - 2007/2/17/pubmed PY - 2007/10/10/medline PY - 2007/2/17/entrez SP - 1 EP - 12 JF - Seminars in arthritis and rheumatism JO - Semin Arthritis Rheum VL - 37 IS - 1 N2 - OBJECTIVE: To provide a review of current developments in bisphosphonates indicated for the treatment of several rheumatologic conditions, including postmenopausal and glucocorticoid-induced osteoporosis. METHODS: This review summarizes the pathology, diagnosis, and treatment of both postmenopausal and glucocorticoid-induced osteoporosis and examines the results of current clinical trials of the newest oral and intravenous formulations of nitrogen-containing bisphosphonates. We discuss important adverse events, including upper gastrointestinal symptoms and osteonecrosis of the jaw. Additionally, we explore methods that may improve patient adherence to bisphosphonate therapy, which is currently suboptimal. RESULTS: Clinical studies have shown that oral bisphosphonates are efficacious in increasing bone mineral density and reducing risk of fracture. Despite concerns of upper gastrointestinal irritation, most of the newer oral bisphosphonates display a safety profile similar to placebo. Many of the newest formulations offer patients a choice in both dosing frequency and method of administration (either oral or intravenous). CONCLUSIONS: Nitrogen-containing bisphosphonates are important therapeutic options for the prevention and treatment of osteoporosis. SN - 0049-0172 UR - https://www.unboundmedicine.com/medline/citation/17303219/Recent_developments_in_bisphosphonate_therapy_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0049-0172(06)00183-1 DB - PRIME DP - Unbound Medicine ER -